What kind of medicine is pemetinib? Is it included in medical insurance?

Pemetinib (pemetinib) is an innovative small molecule targeted drug specifically designed to treat advanced, metastatic or unresectable cholangiocarcinoma withFGFR2 fusion or rearrangement. This drug was developed by Incyte Corporation and has been approved by the US FDA for marketing, providing a new treatment option for patients with cholangiocarcinoma.

The main mechanism of action of pemetinib is to prevent the growth and spread of tumors by inhibiting FGFR kinases in tumor cells, especially FGFR2 and FGFR1. In clinical trials, pemetinib has shown significant efficacy. For patients with cholangiocarcinoma, it can achieve an objective response rate of approximately 35.5%, and a disease control rate as high as 82%. This means that pemetinib can not only shrink or eliminate tumors in some patients, but can also stabilize or slow the progression of the disease in most patients.

In addition, the median duration of response to pemetinib was9.1 months, indicating that its efficacy is durable. At the same time, the safety of the drug has also been verified, but it is still necessary to pay attention to possible adverse reactions, such as diarrhea, nausea, etc.

Pemetinib is currently on the market in China, but unfortunately this drug has not yet been included in domestic medical insurance reimbursement items. The original version of pemetinib available in China is 4.5mg*14 tablets, and the price is around 30,000 yuan. Patients who need pemetinib can purchase the original drug directly from domestic hospitals. In addition, patients can also consider different versions of pemetinib available overseas. It is understood that foreign versions of pemetinib include original research version and generic version. The original version of pemetinib is marketed abroad in a box of 13.5mg*14 tablets and the price is about 72,000 yuan; the generic version of pemetinib is produced by Lucius Pharmaceuticals in Laos, and the specification in a box is 4.5mg*14 tablets and the price is only about 850 yuan. If patients have questions about pemetinib, please consult a regular overseas medical company.

Overall, pemetinib brings new treatment hope to patients with cholangiocarcinoma due to its unique molecular mechanism and significant efficacy. It can not only improve the patient's quality of life, but also potentially extend the patient's survival. However, as a prescription drug, it must be used strictly according to medical instructions to ensure safety and effectiveness.